News

A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech (NASDAQ: BNTX) stock on Monday. As of late-session trading that day, the once-hot biotech's share price had

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q2 2023 Earnings CallAug 01, 2023, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are

In June, UnitedHealth Group (NYSE: UNH) alerted investors that its costs were creeping up due to increasing demand for surgeries. That led to a decline in the share price heading into the company's

With a market cap of $472 billion and tens of millions of people covered under its plans, UnitedHealth Group (NYSE: UNH) is the undisputed king of health insurance stocks. But over the last 12

On July 18, Pfizer (NYSE: PFE) announced that it is forging a strategic alliance with Flagship Pioneering, a venture capital (VC) firm, in which the pair would invest $50 million each into 10

Equity markets can be volatile, erratic, and not always entirely rational. That sometimes results in shares of companies not being adequately priced. And when these stocks trade for less than

Companies that possess the characteristic of consistency are arguably the foundation upon which all income portfolios should be built. That is because businesses that reliably grow over time can

There's no healthcare company that's worth anywhere near $1 trillion today. But within the next 10 years, that's likely to change, given the many growth opportunities emerging in the industry. Two

You need money to make money with stocks. While there's no minimum you have to invest, $5,000 is a good figure I strive for as a minimum. It means you've got some decent skin in the game where

Big insurer UnitedHealth (NYSE: UNH) was the very picture of health, at least as far as its stock was concerned on Tuesday. Its price rose by a sprightly 3.3% that day, well eclipsing the 0.7% rise

For a dividend-growth investor, the path to lasting success is as simple as buying and holding businesses that are consistently growing. After all, steadily rising profits drive dividend growth over

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q2 2023 Earnings CallJul 14, 2023, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of UnitedHealth Group (NYSE: UNH), the nation's largest private medical insurer, were up more than 6.6% as of 11 a.m. ET on Friday after the company reported second-quarter earnings. The heal

When you invest in industries that are positioned to capitalize on secular trends, owning wonderful businesses for the long haul is all it takes to build wealth and passive income. As the world's

Did you know that if you earned an average of 7% per year, your investment would double in 10 years? That's lower than the S&P 500's long-run average of 10%. Investing in some top growth stocks

UnitedHealth Group (NYSE: UNH) is the largest private health insurance company in the U.S., with more than 400,000 employees. It pulled in $324.2 billion in revenue last year, making it the largest

A good measure of a truly great business is that it outperforms the broader market over the long haul. This is because over the long term total returns tend to be more closely aligned with

Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the

Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The